Liu Huanbing, Chen Yong, Qin Xiaowei, Jin Zheng, Jiang Yining, Wang Yubo
Department of Neurosurgery, First Affiliated Hospital of Jilin University, Changchun, China.
Front Oncol. 2022 Feb 11;12:789856. doi: 10.3389/fonc.2022.789856. eCollection 2022.
We aimed to analyze the epidemiology and outcomes of pediatric patients and adult patients with optic pathway gliomas in the United States using a population-based method.
Data for patients with optic pathway gliomas diagnosed between 2000 and 2018 were extracted from the SEER database. We divided the patients into a pediatric group and an adult group. Descriptive analyses were conducted to analyze demographic and clinical characteristics and treatment. We used the chi-square test to evaluate differences between pediatric and adult patients with optic pathway gliomas. The possible prognostic indicators were analyzed by Kaplan-Meier curves and Cox proportional hazards models.
Optic pathway gliomas represented 86.6% of all lesions originating from the optic pathway. In total, 1257 cases of optic pathway gliomas were included in our study. Pediatric patients accounted for 83.7% in this cohort, and most of the patients were diagnosed at 1-4 years old. Chemotherapy was chosen most often for pediatric patients, but radiation therapy was chosen most often for adult patients. Pilocytic astrocytoma accounted for 59.1% of pediatric patients and 37.5% of adult patients. The overall survival (OS) rates were 94.8% 5 years after diagnosis and 93.0% 10 years after diagnosis. Survival analysis showed that surgery, radiation and chemotherapy did not help patients obtain a better prognosis. Overall, pediatric patients had a better prognosis.
Optic pathway gliomas are relatively rare lesions with good prognosis. They mostly affect children, and pilocytic astrocytoma is the most common histological diagnosis. Highly individualized treatment is essential for such patients.
我们旨在采用基于人群的方法分析美国小儿和成人视神经通路胶质瘤患者的流行病学及预后情况。
从监测、流行病学和最终结果(SEER)数据库中提取2000年至2018年期间诊断为视神经通路胶质瘤患者的数据。我们将患者分为儿童组和成人组。进行描述性分析以分析人口统计学和临床特征及治疗情况。我们使用卡方检验评估小儿和成人视神经通路胶质瘤患者之间的差异。通过Kaplan-Meier曲线和Cox比例风险模型分析可能的预后指标。
视神经通路胶质瘤占所有起源于视神经通路病变的86.6%。我们的研究共纳入1257例视神经通路胶质瘤病例。该队列中儿童患者占83.7%,大多数患者在1 - 4岁时被诊断。小儿患者最常选择化疗,而成人患者最常选择放疗。毛细胞型星形细胞瘤在小儿患者中占59.1%,在成人患者中占37.5%。诊断后5年总生存率(OS)为94.8%,诊断后10年为93.0%。生存分析表明,手术、放疗和化疗无助于患者获得更好的预后。总体而言,小儿患者预后较好。
视神经通路胶质瘤是相对罕见的病变,预后良好。它们主要影响儿童,毛细胞型星形细胞瘤是最常见的组织学诊断类型。对此类患者进行高度个体化治疗至关重要。